Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| Online-Ressource |
Verfasst von: | Dreger, Peter [VerfasserIn]  |
Titel: | High-risk chronic lymphocytic leukemia in the era of pathway inhibitors |
Titelzusatz: | integrating molecular and cellular therapies |
Verf.angabe: | Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer and Emili Montserrat |
E-Jahr: | 2018 |
Jahr: | 30 August 2018 |
Umfang: | 11 S. |
Fussnoten: | Gesehen am 14.06.2019 |
Titel Quelle: | Enthalten in: Blood |
Ort Quelle: | Washington, DC : American Society of Hematology, 1946 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 132(2018), 9, Seite 892-902 |
ISSN Quelle: | 1528-0020 |
Abstract: | Visual Abstract - <img class="highwire-fragment fragment-image" alt="Figure1" src="http://www.bloodjournal.org/content/bloodjournal/132/9/892/F1.medium.gif" width="411" height="440"/>Download figureOpen in new tabDownload powerpoint - - High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53 abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential. |
DOI: | doi:10.1182/blood-2018-01-826008 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1182/blood-2018-01-826008 |
| Volltext: http://www.bloodjournal.org/content/132/9/892 |
| DOI: https://doi.org/10.1182/blood-2018-01-826008 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1667457365 |
Verknüpfungen: | → Zeitschrift |
High-risk chronic lymphocytic leukemia in the era of pathway inhibitors / Dreger, Peter [VerfasserIn]; 30 August 2018 (Online-Ressource)
68398789